MPPT – Frontiers in Medicine
New MPPT clinical study:
100% closure rate of pressure ulcers

Download Publication

Download Publication

Download Publication

Slider-web-hypoallergenic
Hypoallergenic

Only natural ingredients

Only natural ingredients

Only natural ingredients

previous arrow
next arrow

Chair of the WHO Antimicrobial Resistance (AMR) group

Publication shows that MPPT acts as a passive immunotherapy that interacts with the microbiome and calls for a paradigm shift in the treatment of wounds and ulcers (Sams-Dodd et al. 2018).

In response to these findings, Executive Board member of the World Health Organization (WHO), and chair of the WHO Strategic and Technical Advisory Group on Anti-Microbial-Resistance, Professor Dame Sally Davies, who also serves as England’s Chief Medical Officer and counsel to the British Government, stated:

“Antimicrobial Resistance (AMR) is an escalating global threat that puts millions of lives across the world in danger. We cannot rely on the development of new antibiotics alone to mitigate this threat. We need better preventative measures as well as alternative treatments, including innovative ways to use the body’s own immune system and healthy bacteria. I am proud to say the UK are leaders in research into this area.”

Related Posts